GlassScriptPhysician profile
Diane M Steere
NPI 1164483863
$4,281.69
in general payments reported to CMS, 2019-2025
45 companies · $862 in 2025
The $862 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $393 · 2021: $793 · 2022: $777 · 2023: $546 · 2024: $792 · 2025: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,200.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $772.09 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $676.72 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $281.24 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $225.10 | 2023-2025 | |
| Amarin Pharma, INC. | $184.40 | 2020-2022 | |
| Abbvie INC. | $181.84 | 2020-2023 | Vraylar |
| Glaxosmithkline, LLC. | $173.71 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $172.56 | 2020-2025 | Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $110.26 | 2020-2025 | Spravato |
| Amgen INC. | $101.61 | 2021-2025 | Repatha, Otezla, Otezla |
| Sumitomo Pharma America, INC. | $91.54 | 2023-2025 | Gemtesa |
| Medtronic, INC. | $72.11 | 2023-2025 | Intellis Adaptivestim |
| Astellas Pharma US INC | $69.57 | 2020-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $69.52 | 2020-2022 | |
| Allergan, INC. | $68.90 | 2019-2020 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Steere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.